Overview
To evaluate the efficacy and safety of investigational drug Colchicine combined with conventional lenalidomide based therapy in multiple myeloma subjects who had received first-line therapy (including Chimeric antigen receptor T-Cell immunotherapy (CART) treatment), and to evaluate the quality of life of the patients.
Description
This study is expected to be carried out from March 2022 to December 2024. About 30 patients with multiple myeloma who have received at least first-line of treatment (including Chimeric antigen receptor T-Cell immunotherapy (CART) treatment) will be randomly assigned to the experimental group or the control group at 2:1. By comparing the relevant data such as efficacy evaluation and safety evaluation after treatment, the principal investigator will write and publish the paper.
Eligibility
Inclusion Criteria:
Clinical diagnosis of multiple myeloma Have received at least one-line treatment Must be
able to swallow tablets
Exclusion Criteria:
Resistance to or intolerance to therapeutic agents such as bortezomib or lenalidomide
Allergy to the experimental drug or its ingredients Has invaded the central nervous system
Severe cardiovascular, liver and kidney failure, severe chronic obstructive pulmonary
disease (COPD), and moderate to severe asthma Active hepatitis B or C infection HIV
seropositivity Is participating in other clinical trials or has participated in other
clinical trials within the past two weeks Other factors that the researchers determined
were not suitable for the trial